BUSINESS
Kowa Grants Chugai Exclusive Marketing Rights in Japan for Peretinoin for Prevention of Recurrence of HCC
Kowa and Chugai Pharmaceutical have entered into a license agreement for exclusive marketing rights in Japan to Kowa’s investigational agent peretinoin (development code: NIK-333) for the prevention of recurrence of hepatocellular carcinoma (HCC), the pair said on July 14. Under…
To read the full story
BUSINESS
- Gilead Files CAR-T Therapy Tecartus in Japan for MCL, B-ALL
August 21, 2026
- Tiger, Gaudi Develop Compact Cell Transport Container
August 21, 2026
- Sawai’s Solo Tenelia Copy Raises Patent Questions Ahead of December Listing
August 21, 2026
- DT-Axis Charts Path to 2nd-Stage DTx Approval with Depression App
August 21, 2026
- Amvuttra Key to Alnylam Japan’s 25%-Plus CAGR Goal through 2030
August 20, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…





